ABUS Arbutus Biopharma Corp. presents a perplexing valuation scenario. Despite a robust Earnings Yield of 18.45% and a Forward P/E ratio suggesting potential undervaluation, the market seems to have priced the stock well below its DCF Value. The Altman Z-score of 30.13 indicates exceptional financial stability, yet the Graham Number suggests a more conservative valuation. This discrepancy hints at a market mispricing, potentially offering a lucrative opportunity for savvy investors who can navigate the biotech sector’s inherent volatility.